Ronald Richard - EMERGENT BIOSOLUT Lead Independent Director
| ER4 Stock | EUR 9.49 0.01 0.11% |
Director
Mr. Ronald B. Richard is Lead Independent Director of the Company. Mr. Richard has served as the president and chief executive officer of the Cleveland Foundation, the nation oldest community foundation, since June 2003. From August 2002 to February 2003, Mr. Richard served as president of Stem Cell Preservation, Inc., a startup medical research company. After leaving Stem Cell Preservation and prior to joining our board of directors, Mr. Richard served as a strategic business advisor for IGEN International, Inc., a biotechnology company. Mr. Richard served as chief operating officer of InQTel, a VC fund that provides technologies to the Central Intelligence Agency, from March 2001 to August 2002. Prior to joining InQTel, Mr. Richard served in various senior management positions at Matsushita Electric, a consumer electronics company. Mr. Richard is a former U.S. foreign service officer. He served in OsakaKobe, Japan and as a desk officer for North Korean, Greek and Turkish affairs at the U.S. Department of State in Washington, D.C. Mr. Richard previously served as chairman of the board of trustees of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University since 2014.
| Age | 63 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
Ronald Richard Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ronald Richard against EMERGENT BIOSOLUT stock is an integral part of due diligence when investing in EMERGENT BIOSOLUT. Ronald Richard insider activity provides valuable insight into whether EMERGENT BIOSOLUT is net buyers or sellers over its current business cycle. Note, EMERGENT BIOSOLUT insiders must abide by specific rules, including filing SEC forms every time they buy or sell EMERGENT BIOSOLUT'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ronald Richard over a month ago Acquisition by Ronald Richard of 33847 shares of Emergent Biosolutions subject to Rule 16b-3 |
Similar Executives
| Found 7 records | DIRECTOR Age | ||
| Jane Carlin | The Hanover Insurance | 63 | |
| Wendell Knox | The Hanover Insurance | 71 | |
| Joseph Ramrath | The Hanover Insurance | 62 | |
| Kathleen Lane | The Hanover Insurance | 61 | |
| Harriett Taggart | The Hanover Insurance | 71 | |
| Kevin Bradicich | The Hanover Insurance | 61 | |
| Daniel Henry | The Hanover Insurance | 69 | |
EMERGENT BIOSOLUT Leadership Team
Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Sean Kirk, Executive Vice President Manufacturing and Technical Operations | ||
| Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Marvin White, Director | ||
| Kathryn Zoon, Independent Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Adam Havey, Executive Vice President and Presidentident - BioDefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Independent Director | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
EMERGENT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.